Announcements Trials
Browse Landscape

Phase

Phase 1/2 6Phase 2 5Phase 1 4Phase 3 1

Status

Completed 8Withdrawn 7Terminated 5Active not recruiting 2Unknown 1

Sponsor Class

OTHER 3INDUSTRY 2

Study Type

Interventional 5

Sponsor

Cancer Type

Head & Neck 2Sarcoma 1Gynecologic 1Genitourinary 1Gastrointestinal 1

Conditions

Squamous Cell Carcinoma of Head and Neck 2Ovarian Neoplasms 1Neoplasms 1Head and Neck Neoplasms 1Gastrointestinal Stromal Tumors 1Carcinoma, Transitional Cell 1

Interventions

Cyclophosphamide 166Docetaxel 154Bevacizumab 153Carboplatin 148Gemcitabine 146Cisplatin 146pembrolizumab 142Radiotherapy 135Paclitaxel 132Capecitabine 122Rituximab 115Oxaliplatin 104Fluorouracil 103Nivolumab 94Irinotecan 85Doxorubicin 85Pemetrexed 83Leucovorin 82Dexamethasone 82fludarabine 74fludarabine phosphate 72Bortezomib 69Etoposide 67Erlotinib Hydrochloride 66Cetuximab 65Methotrexate 58Trastuzumab 56Cytarabine 54Lenalidomide 50Everolimus 49

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

5 trials
RecentStart dateEnrollment
Phase 2 × Terminated × epacadostat × Clear all
NCT04586244 2025-10-30

Optimus

Incyte Corporation

Phase 2 Terminated
30 enrolled 12 charts
Genitourinary

Carcinoma, Transitional Cell

NCT03291054 2024-06-11

Epacadostat and Pembrolizumab in Patients With GIST

Columbia University

Phase 2 Terminated
1 enrolled 1 chart
GastrointestinalSarcoma

Gastrointestinal Stromal Tumors

NCT03823131 2023-05-09

Optimizing Antitumor Immunity Using Plasmid Electroporation, Pembrolizumab, and Epacadostat

University of California, San Francisco

Phase 2 Terminated
14 enrolled 12 charts
Head & Neck

Squamous Cell Carcinoma of Head and Neck

NCT03463161 2020-01-27

ORKA

University of Chicago

Phase 2 Terminated
2 enrolled 5 charts
Head & Neck

Squamous Cell Carcinoma of Head and Neck, Head and Neck Neoplasms

NCT01685255 2019-03-11

A Phase 2 Study of the IDO Inhibitor Epacadostat Versus Tamoxifen for Subjects With Biochemical-recurrent-only EOC, PPC or FTC Following Complete Remission With First-line Chemotherapy

Incyte Corporation

Phase 2 Terminated
83 enrolled
Gynecologic

Neoplasms, Ovarian Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡